Blurblogs
Global
Popular
Log in
sarcozona's blurblog
plant lover, cookie monster, shoe fiend
16930 stories
·
20 followers

Folks who insist on “data are” don’t understand how language works | Scientist Sees Squirrel
Tuesday April 30th, 2024 at 9:52 AM

Scientist Sees Squirrel
1 Comment
Read the whole story
sarcozona
1 hour ago
reply
My supervisor insists on data are and it kills me
Epiphyte City
Share this story
Delete

Location, location location: Why real estate's golden rule also applies to morel mushrooms | CBC News
Tuesday April 30th, 2024 at 9:04 AM

1 Comment

It turns out morel mushrooms and real estate have something in common.

Location, location, location is the golden rule for buying or selling a home as much as it is for morels — the elusive and prized edible variety of mushroom that often grows in the same place every year and, according to a fungus expert, can be potentially dangerous depending on where you pick them. 

Morels are brown, black or yellow and have elongated caps with a ridged and pitted appearance that resembles a honeycomb. With a strong and distinct flavour, they're prized by chefs and amateur cooks alike for their ability to bring new life to dishes. 

For those in the know, places where morels grow are closely guarded secrets. For the uninitiated, finding them while out on a walk in the woods is rare, according to Andrew Murray, an amateur naturalist who often spends his free time admiring the beauty of nature.

"I just take pictures and leave them be," he said, noting he's never eaten one. "They're quite rare in my experience. I see maybe one every few years. The last one was in 2021." 

False and true morels easy to discern

The mushroom's elusive nature and coveted status might be why people seem to be so keen to put pictures of them online every spring. 

Over the past few weeks, morel hunters across Canada have been posting their hauls to social media groups — from a lonesome mushroom plucked from the lawn by a suburban dad, to morels gathered by the dozen, harvested from a top-secret hunting ground.  

Murray doesn't eat them because there are false morels out there and, as he puts it, "I don't trust my fungal identification skills."

False morels can cause severe illness and, in rare cases, death if ingested, according to the UBC Beaty Biodiversity Museum in Vancouver.

The good news is spotting the difference between a false morel and a real one is relatively easy, said Greg Thorn, a biology professor at Western University in London, Ont., who studies fungus.

"The false morel looks more like the brain on a stick than a honeycomb, so it has quite a different morphology," he said, noting, "'false morel' is just called that because they occur at the same season in the spring when there's not very many other mushrooms out there."

Morel lesson: Stick to conservation areas, parks 

Thorn said the most important consideration for morel hunters is where they harvest their mushrooms. Morels have a tendency to absorb and concentrate toxins found in their environments, according to research.

"They're renowned for taking up toxins in the soil, including metals like lead, or cadmium or arsenic." He noted that while abandoned apple orchards are prime locations for morel hunting, they should be avoided because of the historical reliance on arsenic-based pesticides on apple crops. 

A 2010 study found concentrations of lead and arsenic in morel mushrooms harvested from a former apple orchard in New Jersey;  a 2018 study found concentrations of radionucleides from wild mushrooms gathered in Chornobyl, the site of an accident at its nuclear power plant in 1986.

Thorn said mushrooms are the fruiting body of a much larger organism that lives underground, a vast hidden network of filaments and threads that take nutrients from soil or a rotten log. 

"Fungi, for whatever reason, we don't know why they don't discriminate between compounds they do need and compounds they don't need, like a radioactive cesium," Thorn said. "They're very, very good at concentrating these compounds.

"You really don't want to be eating a dinner of radioactive cesium or arsenic."

It's why Thorn recommends sticking to conservation areas or parks to gather mushrooms and to avoid areas that are known to be polluted, such as abandoned apple orchards or brownfield sites. 

Thorn said that given the early spring, it's likely this year's morel season will stretch well into May, meaning the mushrooms could continue to sprout until Mother's Day on May 12.

Read the whole story
sarcozona
1 hour ago
reply
I have morels growing in my artichoke tub this year!
Epiphyte City
Share this story
Delete

An economic evaluation of eptinezumab for the preventive treatment of migraine in the UK, with consideration for natural history and work productivity | The Journal of Headache and Pain | Full Text
Tuesday April 30th, 2024 at 1:35 AM

1 Share

  1. Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38(1):1–211. https://doi.org/10.1177/0333102417738202

    Article  Google Scholar 

  2. GBD 2019 Diseases and Injuries Collaborators (2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet 396(10258):1204–1222. https://doi.org/10.1016/S0140-6736(20)30925-9

    Article  Google Scholar 

  3. Institute for Health Metrics and Evaluation (2019) GBD Compare https://vizhub.healthdata.org/gbd-compare/. Accessed 17 Apr 2023

  4. Affatato O, Miguet M, Schiöth HB, Mwinyi J (2021) Major sex differences in migraine prevalence among occupational categories: a cross-sectional study using UK Biobank. J Headache Pain 22(1):145. https://doi.org/10.1186/s10194-021-01356-x

    Article  PubMed  PubMed Central  Google Scholar 

  5. Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton RB (2003) The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia 23(7):519–527. https://doi.org/10.1046/j.1468-2982.2003.00568.x

    Article  CAS  PubMed  Google Scholar 

  6. Buse D, Manack A, Serrano D, Reed M, Varon S, Turkel C, Lipton R (2012) Headache impact of chronic and episodic migraine: results from the American migraine prevalence and prevention study. Headache 52(1):3–17. https://doi.org/10.1111/j.1526-4610.2011.02046.x

    Article  PubMed  Google Scholar 

  7. Buse DC, Reed ML, Fanning KM, Bostic R, Dodick DW, Schwedt TJ et al (2020) Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study. J Headache Pain 21(1):23. https://doi.org/10.1186/s10194-020-1084-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Buse DC, Reed ML, Fanning KM, Bostic RC, Lipton RB (2020) Demographics, headache features, and comorbidity profiles in relation to headache frequency in people with migraine: results of the American Migraine Prevalence and Prevention (AMPP) study. Headache. https://doi.org/10.1111/head.13966

    Article  PubMed  PubMed Central  Google Scholar 

  9. Munjal S, Singh P, Reed ML, Fanning K, Schwedt TJ, Dodick DW et al (2020) Most bothersome symptom in persons with migraine: results from the Migraine in America symptoms and treatment (MAST) study. Headache 60(2):416–429. https://doi.org/10.1111/head.13708

    Article  PubMed  Google Scholar 

  10. Walters AB, Hamer JD, Smitherman TA (2014) Sleep disturbance and affective comorbidity among episodic migraineurs. Headache 54(1):116–124. https://doi.org/10.1111/head.12168

    Article  PubMed  Google Scholar 

  11. Brown JS, Neumann PJ, Papadopoulos G, Ruoff G, Diamond M, Menzin J (2008) Migraine frequency and health utilities: findings from a multisite survey. Value Health 11(2):315–321. https://doi.org/10.1111/j.1524-4733.2007.00246.x

    Article  PubMed  Google Scholar 

  12. Buse DC, Fanning KM, Reed ML, Murray S, Dumas PK, Adams AM, Lipton RB (2019) Life with migraine: effects on relationships, career, and finances from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache 59(8):1286–1299. https://doi.org/10.1111/head.13613

    Article  PubMed  PubMed Central  Google Scholar 

  13. Lampl C, Thomas H, Stovner LJ, Tassorelli C, Katsarava Z, Laínez JM et al (2016) Interictal burden attributable to episodic headache: findings from the eurolight project. J Headache Pain 17:9. https://doi.org/10.1186/s10194-016-0599-8

    Article  PubMed  PubMed Central  Google Scholar 

  14. The Work Foundation (2018) Society’s headache. The socioeconomic impact of migraine. https://www.lancaster.ac.uk/media/lancaster-university/content-assets/documents/lums/work-foundation/SocietysHeadacheTheSocioeconomicimpactofmigraine.pdf. Accessed 17 Apr 2023.

  15. Ford J, Nichols RM, Ye W, Tockhorn-Heidenreich A, Cotton S, Jackson J (2021) Patient-reported outcomes for migraine in the US and Europe: burden Associated with multiple preventive treatment failures. Clinico econ Outc Res. 13:647–60. https://doi.org/10.2147/CEOR.S304158

    Article  Google Scholar 

  16. Goadsby PJ, Evers S (2020) International classification of Headache disorders - ICHD-4 alpha. Cephalalgia 40(9):887–888. https://doi.org/10.1177/0333102420919098

    Article  PubMed  Google Scholar 

  17. Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen CL, Josiassen MK et al (2022) Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 21(7):597–607. https://doi.org/10.1016/S1474-4422(22)00185-5

    Article  CAS  PubMed  Google Scholar 

  18. Barbanti P, Goadsby PJ, Lambru G, Ettrup A, Christoffersen CL, Josiassen MK et al (2022) Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study. J Headache Pain 23(1):153. https://doi.org/10.1186/s10194-022-01521-w

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. EMC, Summary of product characteristics (2023) VYEPTI 100 mg concentrate for solution for infusion. https://www.medicines.org.uk/emc/product/13243/smpc. Accessed 17 Apr 2023

  20. National Institute for Health and Care Excellence (NICE) (2020) TA659: Galcanezumab for preventing migraine. https://www.nice.org.uk/guidance/TA659. Accessed 17 Apr 2023

  21. National Institute for Health and Care Excellence (NICE) (2021) TA682: Erenumab for preventing migraine. https://www.nice.org.uk/guidance/ta682. Accessed 17 Apr 2023

  22. National Institute for Health and Care Excellence (NICE) (2022) TA764: Fremanezumab for preventing migraine. https://www.nice.org.uk/guidance/TA764. Accessed 17 Apr 2023

  23. National Institute for Health and Care Excellence (NICE) (2023) TA871: Eptinezumab for preventing migraine. https://www.nice.org.uk/guidance/ta871/. Accessed 17 Apr 2023

  24. National Institute for Health and Care Excellence (NICE) (2022) NICE health technology evaluations: the manual. https://www.nice.org.uk/process/pmg36/. Accessed 17 April 2023

  25. NHS England (2022) What are integrated care systems? https://www.england.nhs.uk/integratedcare/what-is-integrated-care/. Accessed 8 May 2023

  26. The King’s Fund (2022) Integrated care systems explained: making sense of systems, places and neighbourhoods. https://www.kingsfund.org.uk/publications/integrated-care-systems-explained. Accessed 8 May 2023

  27. Kernick D, Kondori N, Pain A, Mount J, Appel C, Ranopa M, Gulati T (2024) Preventive treatment patterns in the adult migraine population: an observational UK study over 7 years. BMC Primary Care 25(1):34. https://doi.org/10.1186/s12875-023-02242-y

    Article  PubMed  PubMed Central  Google Scholar 

  28. Office for National Statistics (ONS) (2021) National Life Tables: England. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/bulletins/nationallifetablesunitedkingdom/2018to2020. Accessed 17 Apr 2023

  29. Karnon J, Haji Ali Afzali H (2014) When to use discrete event simulation (DES) for the economic evaluation of health technologies? A review and critique of the costs and benefits of DES. Pharmacoeconomics 32(6):547–558. https://doi.org/10.1007/s40273-014-0147-9

    Article  PubMed  Google Scholar 

  30. Ailani J, Burch RC, Robbins MS (2021) The American headache society consensus statement: update on integrating new migraine treatments into clinical practice. Headache 61(7):1021–1039. https://doi.org/10.1111/head.14153

    Article  PubMed  Google Scholar 

  31. Raffaelli B, Terhart M, Overeem LH, Mecklenburg J, Neeb L, Steinicke M, Reuter U (2022) Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. Cephalalgia 42(4–5):326–334. https://doi.org/10.1177/03331024211046617

    Article  PubMed  Google Scholar 

  32. Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R et al (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update. J Headache Pain 23(1):67. https://doi.org/10.1186/s10194-022-01431-x

    Article  PubMed  PubMed Central  Google Scholar 

  33. Manack A, Buse DC, Serrano D, Turkel CC, Lipton RB (2011) Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology 76(8):711–718. https://doi.org/10.1212/WNL.0b013e31820d8af2

    Article  CAS  PubMed  Google Scholar 

  34. Roy J, Stewart WF (2011) Methods for estimating remission rates from cross-sectional survey data: application and validation using data from a national migraine study. Am J Epidemiol 173(8):949–955

    Article  PubMed  Google Scholar 

  35. Serrano D, Lipton RB, Scher AI, Reed ML, Stewart WF, Adams AM, Buse DC (2017) Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain 18(1):101. https://doi.org/10.1186/s10194-017-0787-1

    Article  PubMed  PubMed Central  Google Scholar 

  36. Krause DN, Warfvinge K, Haanes KA, Edvinsson L (2021) Hormonal influences in migraine — interactions of oestrogen, oxytocin and CGRP. Nat Reviews Neurol 17(10):621–633. https://doi.org/10.1038/s41582-021-00544-2

    Article  CAS  Google Scholar 

  37. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, Group obotAA (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68(5):343–349. https://doi.org/10.1212/01.wnl.0000252808.97649.21

    Article  CAS  PubMed  Google Scholar 

  38. Pokoradi AJ, Iversen L, Hannaford PC (2011) Factors associated with age of onset and type of menopause in a cohort of UK women. Am J Obstet Gynecol 205(1):34e1–3413. https://doi.org/10.1016/j.ajog.2011.02.059

    Article  Google Scholar 

  39. Paramsothy P, Harlow SD, Nan B, Greendale GA, Santoro N, Crawford SL et al (2017) Duration of the menopausal transition is longer in women with young age at onset: the multiethnic study of women’s Health across the Nation. Menopause 24(2):142–149. https://doi.org/10.1097/gme.0000000000000736

    Article  PubMed  PubMed Central  Google Scholar 

  40. Kudrow D, Cady RK, Allan B, Pederson SM, Hirman J, Mehta LR, Schaeffler BA (2021) Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. BMC Neurol 21(1):126. https://doi.org/10.1186/s12883-021-02123-w

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. GSK (1998) Migraine-Specific Quality-of-Life Questionannaire (MSQ Version 2.1). https://eprovide.mapi-trust.org/instruments/migraine-specific-quality-of-life-questionnaire. Accessed July 2023

  42. Gillard PJ, Devine B, Varon SF, Liu L, Sullivan SD (2012) Mapping from disease-specific measures to health-state utility values in individuals with migraine. Value Health 15(3):485–494. https://doi.org/10.1016/j.jval.2011.12.007

    Article  PubMed  Google Scholar 

  43. EuroQol (2019) EQ-5D-5L User Guide. https://euroqol.org/publications/user-guides/. Accessed July 2023 2023

  44. Jonsson L, Regnier SA, Kymes S, Awad SF, Talon B, Lee XY, Goadsby PJ (2023) Estimating treatment effects on health utility scores for patients living with migraine: a post hoc analysis of the DELIVER trial. Expert Rev Pharmacoecon Outcomes Res 23:1–7. https://doi.org/10.1080/14737167.2023.2219898

    Article  Google Scholar 

  45. Goadsby PJ, Barbanti P, Lambru G, Ettrup A, Christoffersen CL, Josiassen MK et al (2023) Eptinezumab improved patient-reported outcomes and quality of life in patients with migraine and prior preventive treatment failures. Eur J Neurol 30(4):1089–1098. https://doi.org/10.1111/ene.15670

    Article  PubMed  Google Scholar 

  46. NICE (2022) British National Formulary (BNF). https://bnf.nice.org.uk. Accessed 17 Apr 2023

  47. National Institute for Health and Care Excellence (NICE) (2010) Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor. https://www.nice.org.uk/guidance/ta195. Accessed 7 July 2023

  48. NHS England. 2019/20 National Cost Collection Data Publication 2021 [updated 27 July 2022]. Available from: https://www.england.nhs.uk/publication/2019-20-national-cost-collection-data-publication/. Accessed 17 Apr 2023

  49. Curtis LAB (2020) Amanda. Unit Costs of Health & Social Care 2020. PSSRU University of Kent, Kent Academic Repository

    Google Scholar 

  50. Barbanti P, Awad SF, Regnier SA, Lee X, Goadsby PJ (2023) Impact of eptinezumab on work productivity beyond reductions in monthly migraine days: Post hoc analysis of the DELIVER trial (P13-12.012). Neurology 100(17 Supplement 2):3020. https://doi.org/10.1212/WNL.0000000000202965

    Article  Google Scholar 

  51. Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barré J, Katsarava Z et al (2012) The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol 19(5):703–711. https://doi.org/10.1111/j.1468-1331.2011.03612.x

    Article  CAS  PubMed  Google Scholar 

  52. Office for National Statistics (ONS) (2022) Earnings and employment from Pay As You Earn Real Time Information, UK: June 2022. https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/earningsandworkinghours/bulletins/earningsandemploymentfrompayasyouearnrealtimeinformationuk/june2022. Accessed 7 July 2023.

  53. Office for National Statistics (ONS): Labour market overview, UK (2020) https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/employmentandemployeetypes/bulletins/uklabourmarket/january2020. Accessed 7 July 2023

  54. Khanal S, Underwood M, Naghdi S, Brown A, Duncan C, Matharu M, Mistry H (2022) A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine. J Headache Pain 23(1):122. https://doi.org/10.1186/s10194-022-01492-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Sussman M, Benner J, Neumann P, Menzin J (2018) Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: results from the US societal and payer perspectives. Cephalalgia 38(10):1644–1657. https://doi.org/10.1177/0333102418796842

    Article  PubMed  Google Scholar 

  56. Mahon R, Lang A, Vo P, Huels J, Cooney P, Danyliv A et al (2021) Cost-effectiveness of erenumab for the preventive treatment of migraine in patients with prior treatment failures in Sweden. Pharmacoeconomics 39(3):357–372. https://doi.org/10.1007/s40273-020-00996-2

    Article  PubMed  Google Scholar 

  57. Shemilt I, James T, Marcello M (2010) A web-based tool for adjusting costs to a specific target currency and price year. Evid Policy 6(1):51–59. https://doi.org/10.1332/174426410x482999

    Article  Google Scholar 

  58. National Institute for Health and Care Excellence (NICE) (2012) TA260: Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. https://www.nice.org.uk/guidance/TA260. Accessed 17 Apr 2023

  59. Lipton RB, Silberstein SD (2015) Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache 55(Suppl 2):103–22. https://doi.org/10.1111/head.12505_2. quiz 23–6

    Article  PubMed  Google Scholar 

  60. Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2018) Effect of Fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319(19):1999–2008

    Article  CAS  PubMed  Google Scholar 

  61. Fund (2020) TKs: Integrated care systems explained: making sense of systems, places and neighbourhoods. https://www.kingsfund.org.uk/publications/integrated-care-systems-explained. Accessed

Page 2

Results over 12 weeks of treatment, with standard error (SE)

TF3+ EM,

 ≥ 50% reduction in MMDs

TF3+ CM,

 ≥ 30% reduction in MMDs

TF3+ CM,

 ≥ 50% reduction in MMDs (scenario)

Responder rate, BSC, %

9.6 (2.0)

23.2 (4.6)

8.9 (1.8a)

Responder rate, eptinezumab 100mg, %

40.0 (8.0)

63.4 (12.9)

30.4 (6.1a)

Change from baseline in MMDs, BSC responders

-5.82 (1.50)

-8.80 (1.99)

-10.45 (1.41)

Change from baseline in MMDs, eptinezumab 100 mg responders

-6.82 (0.92)

-9.93 (1.41)

-12.68 (1.40)

Change from baseline in MMDs, BSC non-responders

-1.31 (0.84)

-0.85 (1.42)

-1.94 (0.96)

Change from baseline in MMDs, eptinezumab 100 mg non-responders

-1.39 (1.18)

-1.71 (2.28)

-4.52 (1.17)

  1. Key BSC, best supportive care, CM chronic migraine, EM episodic migraine, MMDs monthly migraine days, SE standard error, TF3+ have tried three or more other preventive treatments that failed
  2. aSE = 20% of mean estimate
Read the whole story
sarcozona
9 hours ago
reply
Epiphyte City
Share this story
Delete

Philippine students are told to stay home as Southeast Asia copes with a sweltering heat wave | PBS NewsHour
Monday April 29th, 2024 at 11:08 PM

PBS NewsHour - The Latest
1 Share

MANILA (AP) — Southeast Asia was coping with a weekslong heat wave on Monday as record-high temperatures led to school closings in several countries and urgent health warnings throughout the region.

Millions of students in all public schools across the Philippines were ordered to stay home Monday after authorities canceled in-person classes for two days. The main advice for everyone, everywhere has been to avoid outdoor activities and drink plenty of water, but the young and the elderly were told to be especially careful.

Cambodia this year is facing the highest temperatures in 170 years, Chan Yutha, a spokesperson for the Ministry of Water Resources and Meteorology, told The Associated Press on Monday. His agency has forecast that temperatures in most parts of the country could reach up to 43 degrees Celsius (109 degrees Fahrenheit) this week.

Myanmar’s meteorological department said Monday that seven townships in the central Magway, Mandalay, Sagaing and Bago regions experienced record-high temperatures. Several towns in Myanmar last week were on lists of the hottest spots worldwide.

Chauk township in Magway, historically the country’s hottest region, saw Myanmar’s highest temperature at 48.2 degrees Celsius (118.8 degrees Fahrenheit), breaking the previous record of 47.4 degrees Celsius (117.3 degrees Fahrenheit) set in 1968.

WATCH: A Brief But Spectacular take on giving climate activism a shot

The Philippines is among the nations worst affected by the sweltering weather in Southeast Asia, where the intense tropical summer heat worsened by humidity forced class cancellations in recent weeks and sparked fears of water shortages, power outages and damage to agricultural crops.

The Department of Education ordered students in more than 47,000 public schools to switch to home-based and online learning due to health risks from record-high temperatures and a three-day strike starting Monday by drivers who oppose a government program they fear would remove dilapidated passenger jeepneys from streets.

Large crowds have sought relief in air-conditioned shopping malls in Metropolitan Manila, the congested capital region of more than 14 million people where the temperature soared to 38.8 degrees Celsius (101.84 Fahrenheit) Saturday, surpassing the record set decades ago, according to weather officials.

In Thailand, temperatures have topped 44 C (111 F) in some areas in the northern parts of the country, while the capital Bangkok and metropolitan areas have seen temperatures go above 40 C (104 F). The forecast from the Meteorological Department said this year’s summer, which usually lasts from late February to late May, is expected to be 1-2 degrees hotter than last year, and rainfall will be lower than average.

Thailand’s Department of Disease Control said last week that at least 30 people have died from heatstroke so far this year, compared to 37 for all of last year.

Scientists have said the number of heat-related deaths around the world has been rising significantly in recent years along with temperatures, but the trend in Asia this year so far is unclear, partly because of the question of how to classify deaths that appear to be heat related.

At least 34 people have fallen ill due to the extreme heat in the Philippines so far this year, including six who died. The Department of Health said it was verifying what exactly caused the deaths.

Media in Bangladesh reported that in a five-day period earlier this month, at least 20 people died from heatstroke.

In Cambodia, however, officials indicated there were few if any heat-related fatalities. The Khmer Times, an online news platform, quoted the head of the Health Department of Phnom Penh, the capital, saying there had been no heat-related deaths or collapses.

Associated Press writers Sopheng Cheang in Phnom Penh, Cambodia and Jintamas Saksornchai in Bangkok contributed to this report.

Read the whole story
sarcozona
11 hours ago
reply
Epiphyte City
Share this story
Delete

anarchopuppy:weirdlylyricalnotes:shouldabeentwins:valoricky:memewhore:This is a ...
Monday April 29th, 2024 at 10:57 AM

Random inflexion
2 Shares

anarchopuppy:

weirdlylyricalnotes:

shouldabeentwins:

valoricky:

memewhore:

This is a stupid conversation! and I’m not going to continue it!


literally so fucking correct

What I’m really proud of is the fact that he made SURE the audience understood why the caller was being an idiot. He made a PERFECT comparison, gave the caller an honest chance to re-evaluate and change his mind. His point landed, everyone knew it, even the caller (note his pause and almost hesitancy after being asked).

But when the caller decided to bulldoze on anyway, because god forbid actually listen to the other person in the conversation, the expert cut him off and refused his time. And good for him.

[VD: A tweet by @ g33kgurli, tweeted at 9:47 PM on Dec 17, 2021. It reads, “Perhaps the best clap back to antivaxxers and antimaskers.” Attached is a video from The Thom Hartmann Program, where Hartmann is talking with a caller. The conversation goes as follows:

Caller: Hey Thom. Uh, I was listening to you for the last hour so, um, I heard survival of the fittest. Um, you know some of us choose not to vaccinate and uh–

Hartmann: You’re nuts, Nicholas.

Caller: –because we work very hard about staying fit, eating healthy, and our natural immune system.

Hartmann: So Nicholas if you’re so healthy, would you have unprotected sex with somebody who has syphilis or gonorrhea?

Caller: You’re missing the point.

Hartmann: No, I’m not missing the point. They’re contagious diseases. Would you have unprotected sex with somebody who has syphilis and gonorrhea and not worry about it because you’re so healthy?

Caller: [pause] No, I wouldn’t do that.

Hartmann: Okay, then why would you expose yourself to covid without having some protection?

Caller: Because the protection is my natural immunity.

Hartmann: No, it’s not. Tell that–

Caller: Yes, yes, my natural immune system–

Hartmann: Tell that to eight hundred thousand dead Americans. Nicholas, this is- this is a stupid conversation and I’m not going to continue it.

/end VD]

Everyone who’s ever died of a disease had an immune system

Read the whole story
sarcozona
1 day ago
reply
Epiphyte City
Nadezh
2 days ago
reply
Melbourne, Australia
Share this story
Delete

I cant believe this tweet is how I find out
Monday April 29th, 2024 at 10:55 AM

Random inflexion
2 Shares

would-you-punt-them:

loredwy:

I cant believe this tweet is how I find out

now all the things you guys have told me about american high schools are starting to make sense

Read the whole story
sarcozona
1 day ago
reply
Epiphyte City
Nadezh
2 days ago
reply
Melbourne, Australia
Share this story
Delete
Next Page of Stories